114 related articles for article (PubMed ID: 28224663)
41. Defective Mismatch Repair Status was not Associated with DFS and OS in Stage II Colon Cancer Treated with Adjuvant Chemotherapy.
Kim JE; Hong YS; Kim HJ; Kim KP; Lee JL; Park SJ; Lim SB; Park IJ; Kim CW; Yoon YS; Yu CS; Kim JC; Hoon KJ; Kim TW
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S630-7. PubMed ID: 26271397
[TBL] [Abstract][Full Text] [Related]
42. Redundant DNA methylation in colorectal cancers of Lynch-syndrome patients.
Alemayehu A; Sebova K; Fridrichova I
Genes Chromosomes Cancer; 2008 Oct; 47(10):906-14. PubMed ID: 18618713
[TBL] [Abstract][Full Text] [Related]
43. Mismatch repair deficiency testing in clinical practice.
Buza N; Ziai J; Hui P
Expert Rev Mol Diagn; 2016; 16(5):591-604. PubMed ID: 26895074
[TBL] [Abstract][Full Text] [Related]
44. BRAF-V600E is not involved in the colorectal tumorigenesis of HNPCC in patients with functional MLH1 and MSH2 genes.
Domingo E; Niessen RC; Oliveira C; Alhopuro P; Moutinho C; Espín E; Armengol M; Sijmons RH; Kleibeuker JH; Seruca R; Aaltonen LA; Imai K; Yamamoto H; Schwartz S; Hofstra RM
Oncogene; 2005 Jun; 24(24):3995-8. PubMed ID: 15782118
[TBL] [Abstract][Full Text] [Related]
45. Extended microsatellite analysis in microsatellite stable, MSH2 and MLH1 mutation-negative HNPCC patients: genetic reclassification and correlation with clinical features.
Schiemann U; Müller-Koch Y; Gross M; Daum J; Lohse P; Baretton G; Muders M; Mussack T; Kopp R; Holinski-Feder E
Digestion; 2004; 69(3):166-76. PubMed ID: 15118395
[TBL] [Abstract][Full Text] [Related]
46. DNA-PKcs interference sensitizes colorectal cancer cells to a mTOR kinase inhibitor WAY-600.
Wu L; Zhang J; Wu H; Han E
Biochem Biophys Res Commun; 2015 Oct; 466(3):547-53. PubMed ID: 26381179
[TBL] [Abstract][Full Text] [Related]
47. Mismatch repair deficiency in Lynch syndrome-associated colorectal adenomas is more prevalent in older patients.
Tanaka M; Nakajima T; Sugano K; Yoshida T; Taniguchi H; Kanemitsu Y; Nagino M; Sekine S
Histopathology; 2016 Aug; 69(2):322-8. PubMed ID: 26826556
[TBL] [Abstract][Full Text] [Related]
48. Prevalence and clinicopathologic/molecular characteristics of mismatch repair-deficient colorectal cancer in the under-50-year-old Japanese population.
Suzuki O; Eguchi H; Chika N; Sakimoto T; Ishibashi K; Kumamoto K; Tamaru JI; Tachikawa T; Akagi K; Arai T; Okazaki Y; Ishida H
Surg Today; 2017 Sep; 47(9):1135-1146. PubMed ID: 28258479
[TBL] [Abstract][Full Text] [Related]
49. Association between deficient mismatch repair system and efficacy to irinotecan-containing chemotherapy in metastatic colon cancer.
Kim JE; Hong YS; Ryu MH; Lee JL; Chang HM; Lim SB; Kim JH; Jang SJ; Kim MJ; Yu CS; Kang YK; Kim JC; Kim TW
Cancer Sci; 2011 Sep; 102(9):1706-11. PubMed ID: 21679278
[TBL] [Abstract][Full Text] [Related]
50. Reversal of drug resistance in human tumor xenografts by 2'-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter.
Plumb JA; Strathdee G; Sludden J; Kaye SB; Brown R
Cancer Res; 2000 Nov; 60(21):6039-44. PubMed ID: 11085525
[TBL] [Abstract][Full Text] [Related]
51. Reconstitution of
Bowen N; Kolodner RD
Proc Natl Acad Sci U S A; 2017 Apr; 114(14):3607-3612. PubMed ID: 28265089
[TBL] [Abstract][Full Text] [Related]
52. Somatic mutations in MLH1 and MSH2 are a frequent cause of mismatch-repair deficiency in Lynch syndrome-like tumors.
Mensenkamp AR; Vogelaar IP; van Zelst-Stams WA; Goossens M; Ouchene H; Hendriks-Cornelissen SJ; Kwint MP; Hoogerbrugge N; Nagtegaal ID; Ligtenberg MJ
Gastroenterology; 2014 Mar; 146(3):643-646.e8. PubMed ID: 24333619
[TBL] [Abstract][Full Text] [Related]
53. Expression of DNA mismatch repair proteins MLH1, MSH2, and MSH6 in recurrent glioblastoma.
Stark AM; Doukas A; Hugo HH; Hedderich J; Hattermann K; Maximilian Mehdorn H; Held-Feindt J
Neurol Res; 2015 Feb; 37(2):95-105. PubMed ID: 24995467
[TBL] [Abstract][Full Text] [Related]
54. Coexisting somatic promoter hypermethylation and pathogenic MLH1 germline mutation in Lynch syndrome.
Rahner N; Friedrichs N; Steinke V; Aretz S; Friedl W; Buettner R; Mangold E; Propping P; Walldorf C
J Pathol; 2008 Jan; 214(1):10-6. PubMed ID: 17973250
[TBL] [Abstract][Full Text] [Related]
55. Germline hypermethylation of MLH1 and EPCAM deletions are a frequent cause of Lynch syndrome.
Niessen RC; Hofstra RM; Westers H; Ligtenberg MJ; Kooi K; Jager PO; de Groote ML; Dijkhuizen T; Olderode-Berends MJ; Hollema H; Kleibeuker JH; Sijmons RH
Genes Chromosomes Cancer; 2009 Aug; 48(8):737-44. PubMed ID: 19455606
[TBL] [Abstract][Full Text] [Related]
56. Temozolomide increases the number of mismatch repair-deficient intestinal crypts and accelerates tumorigenesis in a mouse model of Lynch syndrome.
Wojciechowicz K; Cantelli E; Van Gerwen B; Plug M; Van Der Wal A; Delzenne-Goette E; Song JY; De Vries S; Dekker M; Te Riele H
Gastroenterology; 2014 Nov; 147(5):1064-72.e5. PubMed ID: 25088490
[TBL] [Abstract][Full Text] [Related]
57. Loss of mutL homolog-1 (MLH1) expression promotes acquisition of oncogenic and inhibitor-resistant point mutations in tyrosine kinases.
Springuel L; Losdyck E; Saussoy P; Turcq B; Mahon FX; Knoops L; Renauld JC
Cell Mol Life Sci; 2016 Dec; 73(24):4739-4748. PubMed ID: 27436342
[TBL] [Abstract][Full Text] [Related]
58. Somatic mutations in mismatch repair genes in sporadic gastric carcinomas are not a cause but a consequence of the mutator phenotype.
Pinto M; Wu Y; Mensink RG; Cirnes L; Seruca R; Hofstra RM
Cancer Genet Cytogenet; 2008 Jan; 180(2):110-4. PubMed ID: 18206535
[TBL] [Abstract][Full Text] [Related]
59. Epigenetic silencing of MLH1 in endometrial cancers is associated with larger tumor volume, increased rate of lymph node positivity and reduced recurrence-free survival.
Cosgrove CM; Cohn DE; Hampel H; Frankel WL; Jones D; McElroy JP; Suarez AA; Zhao W; Chen W; Salani R; Copeland LJ; O'Malley DM; Fowler JM; Yilmaz A; Chassen AS; Pearlman R; Goodfellow PJ; Backes FJ
Gynecol Oncol; 2017 Sep; 146(3):588-595. PubMed ID: 28709704
[TBL] [Abstract][Full Text] [Related]
60. MLH1-deficient tumor cells are resistant to lipoplatin, but retain sensitivity to lipoxal.
Fedier A; Poyet C; Perucchini D; Boulikas T; Fink D
Anticancer Drugs; 2006 Mar; 17(3):315-23. PubMed ID: 16520660
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
